Home | Back to newsletter main page

Case Comprehensive Cancer Center Newsletter

February 8, 2010


The Case Comprehensive Cancer Center will be featured in a major release from the NCI later this year, celebrating the 40th year that the NCI has been a special institute within the NIH and funded by a separate appropriations process by congress. This special standing represents the nation's commitment to develop an understanding of the etiology, prevention and treatment of cancer.

To show NCI's progress in the war on cancer, the NCI will be issuing a booklet on cancer, with about one half of the book featuring the nation's investment in cancer centers. To compile data for the report, NCI requested information about our cancer center and our accomplishments over the past decade. We responded by providing a description of the center, highlights of major scientific publications, consortium and collaborations, major national positions that our members hold, and an overview of some of our community outreach efforts.

This information is now on our web site at http://cancer.case.edu/news/reports/. Please have a look and refer to it when recruiting colleagues, students and post docs, or to let your friends and family know about this wonderful organization.

Stan Gerson, MD
Director, Case CCC

MESSAGE FROM THE DIRECTOR– Oncomine Software Workshop

Dear Cancer Center Researchers,

At a recent faculty meeting, the subject of purchasing a copy of Oncomine Software was raised. Very few of us knew what this software was or why it would be advantageous for the Cancer Center to have a copy. Soon afterwards, Patrick Leahy of the Gene Expression and Genotyping Facility approached me and lobbied that we purchase a copy for the Cancer Center, arguing that it would be a boon for grant writers leading to stronger grant proposals. Patrick has taken a pro-active approach in organizing a workshop on Oncomine software on March 4 at 2:00 pm in WRB 1413. I hope to be there to evaluate for myself, and I encourage all Cancer Center researchers and their lab personnel to plan to attend. Your feedback on the usefulness of Oncomine Software and your commitment to using it if purchased will be major factors in helping the Center Leadership decide if we should make a financial commitment.

Stan Gerson, MD
Director, Case CCC

PRESIDENTIAL FY2011 BUDGET– NCI to Receive 3.16% Increase

Last week, President Obama released his FY2011 budget which includes a $1 billion increase to the NIH budget. This increase would make the NIH budget $32.1 billion and represent a 3.2% increase. NCI would receive an increase of $161 million, or 3.16%, to $5.26 billion. The budget highlights "more than $6 billion for cancer research to initiate 30 new drug trials in 2011, and double the number of novel compounds in Phase 1 – 3 clinical trials by 2016; and support the completion of a comprehensive catalog of cancer mutations for the 20 most common malignancies, setting the stage for complete genomic characterization of every cancer as part of medical care within 10 years."

Fact Sheet on HHS Portion of Budget

Complete Budget

MARK YOUR CALENDARS– caHUB Development Public Meetings

One of the most widely recognized and significant challenges to progress in cancer research is the lack of standardized, high-quality biospecimens. In response to this challenge, the NCI is planning the development of a national Cancer Human Biobank, called caHUB. caHUB will modernize the field of biobanking and contribute to medical advances by providing high-quality human specimens and data as well as analysis, scientific tools and services to the cancer research and product development communities.

The NCI invites you to attend one of two public meetings to learn more about the caHUB planning process and mission, and review the implementation, structure, timeline and funding process for this national resource. These meetings will bring together academic and government researchers, non-profit foundations, private industries and interested public.

Meeting dates: February 19 (Bethesda, MD) and March 1 (Los Angeles, CA). Both meetings will also be videocast.

For details, please click here.

FUNDING OPPORTUNITY– DOD Prostate Cancer Research Program (PCRP)

The PCRP Exploration–Hypothesis Development Award supports the exploration of highly innovative, untested, high-risk/high-gain concepts, theories, paradigms, and/or methods that address an important problem in prostate cancer. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based, or initial proof-of-principle of an innovative hypothesis. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Presentation of preliminary data is not allowed. However, logical reasoning and a sound scientific rationale for the proposed work must be provided. Open to investigators at or above the level of postdoctoral fellow (or equivalent).

The PCRP Impact Award mechanism is being offered for the first time in FY10. This award will support research projects specifically focused on making a major impact on one critical issue in prostate cancer: reducing or eliminating the over-treatment of primary prostate cancer. PIs applying for the Impact Award are expected to establish a multi-disciplinary study team that may include a variety of clinical specialists to effectively address the proposed question. Projects funded by this award will, if successful, ultimately change the standard of practice for decision-making in the treatment of primary prostate cancer. Open to investigators at or above the Assistant Professor level or equivalent.

Pre-Application Deadline: March 10
Application Deadline: March 31

FUNDING OPPORTUNITY– Samuel Waxman Cancer Research Foundation

The Case CCC has been invited to submit ONE application for a Samuel Waxman Cancer Research Foundation Institute Without Walls grant. Investigators of the Foundation have long been interested in differentiation therapy of cancer- the notion that the cancer cell can be re-programmed to re-acquire aspects of normal cell differentiation including terminal cell division and programmed cell death. In 2010, the Foundation will offer several grants of up to $100,000 per year to fund novel research along these lines.

Applicants must be established investigators with a tenure-track or tenured appointment, holding as PI at least one grant from a major funding source, such as NIH, NSF, DOD or ACS. The applicant may hold a K08, K99/R00, or other major career transition grant, such as those from Burroughs Wellcome Foundation or HHMI. The goal of the program is to leverage existing cancer research expertise into translational and collaborative cancer research.

Please send a one-page proposal and biosketch to Bonnie West (bonnie.west@case.edu) by Monday, February 15. Completed applications are due to Waxman Foundation April 1.

For more information, please click here.


**All events are open to anyone interested in attending

February 8

Pathology Seminar
Charleen Chu, MD, PhD
Associate Professor, Pathology
University of Pittsburgh
Topic: Staying in the PINK1: Mitochondrial Quality Control and Neurodegeneration
12:00 pm WRB 1413

February 9

Immunology Seminar
Martha Cathcart, PhD
Staff, Cell Biology
Cleveland Clinic
Topic: Novel Products of Signal-Activated Phospholipases are Critical for Monocyte Chemotaxis
12:00 pm WRB 1413

Special CSCRM Seminar
Stephen Dalton, PhD
Associate Professor, Biochemistry and Molecular Biology
University of Georgia
Topic: Cardiovascular Progenitors Derived from Human Pluripotent Stem Cells
3:00 pm WRB 1413

February 10

Grand Rounds
Bashar Katirji, MD
Professor, Neurology
Director, Neuromuscular Center & EMG Laboratory, Neurological Institute
Topic: Dysproteinemic Neuropathies
8:00 am Lerner B-151

Neurosciences Seminar
Lyle Fox, PhD
Project Staff, Neuroscience
Cleveland Clinic
Topic: Neuronal Characteristics of Cells Generated from Bone Marrow-Derived Mesenchymal Stem Cells
10:00 am NE1-205 Cleveland Clinic

CSCRM Seminar
Sarah A. Busch, PhD
Fellow, Silver Lab, Neurosciences
CWRU/ Cleveland Clinic
Topic: The Role of Endogenous and Transplanted Stem Cells after Spinal Cord Injury
4:30 pm NA5-08 Cleveland Clinic

February 11

CSCRM Lunch and Learn Seminar
Jerry Ortolano, PhD
Senior VP Scientific Affairs
Pall Medical
Topic: Enabling Translational Medicine Using Filter-Based Cell Recovery Tools
12:00 - 1:30 pm WRB 2-136

Taussig Cancer Institute Core Curriculum Series
David Peereboom, MD
Associate Professor, Hematology & Medical Oncology
CWRU/ Cleveland Clinic
Topic: Brain Metastases
12:00 pm R3-002 Cleveland Clinic

Neurosciences Seminar
Ofer Reizes, PhD
Assistant Professor, Cell Biology
CWRU/ Cleveland Clinic
Topic: Syndecan-3 Null Mice are Wired for Leanness: A Novel Mechanism for Body Weight Regulation
12:10 pm BRB 105

February 12

Hem/Onc Fellows Seminar
Rami Manochakian, MD
Fellow, Div. of Hem/Onc
Topic: Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma
8:00 am Wearn 137

Taussig Cancer Institute Grand Rounds
Richard Larson, MD
Professor, Medicine
University of Chicago
Topic: FLT3-Mutated Acute Myeloid Leukemia-Chemotherapy, Kinase Inhibitors, and Transplantation
8:00 am R3/002-003 Cleveland Clinic

Cancer Center Seminar Series/ Blood Club
Mukesh Jain, MD
Professor, Medicine- Case Cardiovascular Research Institute
Chief Research Officer, Heart & Vascular Institute
Topic: Novel Mechanisms Regulating Macrophage Subsets
12:00 pm BRB 105

Cancer Center Research in Progress Seminar
Yulan Qing, PhD
Research Associate, Gerson Lab, Div. of Hem/Onc
Topic: Ku70 Regulates Hematopoietic Stem Cells Quiescence
4:00 pm WRB 3-136


For a complete listing of LRI seminars click here.


Case CCC Scientific Retreat
July 9-10
The Lodge at Sawmill Creek Resort


12th International Symposium on Anti-Angiogenic Agents: Angio 2010 Recent Advances and Future Directions in Basic and Clinical Cancer Research
February 4-6
Hyatt Regency La Jolla, San Diego, CA

AACR-JCA 8th Joint Conference on Cancer Genomics, Epigenomics, and the Development of Novel Therapeutics
February 5-9
Hilton Waikoloa Village, Waikoloa, HI

13th Annual Meeting of the Translational Research Cancer Centers Consortium
March 1-2
Blackwell Inn, Columbus, OH

AACR 101st Annual Meeting
April 17-21
Washington, DC

FUNDING OPPORTUNITY–Peer Reviewed Medical Research Program (PRMRP)

The objectives of the FY10 PRMRP are to identify and fund the best medical research to protect and support warfighters, veterans, and all beneficiaries, and to eradicate diseases that impact these populations.

PRMRP Clinical Trial Award: support the rapid implementation of clinical trials of interventions with the potential to have a significant impact on a disease or condition addressed in at least one of the congressionally directed FY10 PRMRP topic areas. Open to PIs above Assistant Professor (or equivalent); multi-institutional clinical trials are allowed; collaboration with VA researchers and/or clinicians is encouraged, however, use of military populations is not a prerequisite; all applications must specifically and clearly address the military relevance of the proposed research; award cannot be used to support preclinical research studies.

Pre-Application Deadline: April 22
Application Deadline: May 13

PRMRP Concept Award: support the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to at least one of the FY10 PRMRP topic areas. Innovation and novelty of the concept are the most important aspects of this award mechanism. Inclusion of preliminary data is strongly discouraged. This award is not intended to support ongoing work; therefore, the existence and presentation of preliminary data suggests that the proposed research would be more appropriately submitted to a different award mechanism. Open to all investigators.

Pre-Application Deadline: March 25
Application Deadline: April 8

Investigator-Initiated Research Award: support studies that will make an important contribution toward understanding mechanisms of initiation, or progression of and/or improving patient care for a disease or a condition related to at least one of the congressionally directed FY10 PRMRP topic areas. Open to PIs at or above the level of Assistant Professor (or equivalent); partnering-PI option using a multi-institutional approach; clinical trials are not allowed; research projects may focus on any phase of research from basic laboratory research through translational research.

Pre-Application Deadline: March 11
Application Deadline: August 5

Technology/Therapeutic Development Awards: provide support for the translation of promising preclinical findings into products for clinical applications in at least one of the congressionally directed FY10 PRMRP topic areas. The product(s) to be developed may be pharmacologic agents (drugs or biologicals), devices, and/or clinical guidance. PI must provide a transition plan (including potential funding and resources) showing how the product will progress to clinical trials and/or delivery to the military or civilian market after the completion of the PRMRP award. Open to PIs at or above the level of Assistant Professor (or equivalent); clinical trials are not allowed.

Pre-Application Deadline: April 22
Application Deadline: May 13

MESSAGE FROM DR. ERNEST BORDEN– Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)

The CTC/CEC core has initiated several investigator-initiated pilot studies and has begun to see planning for those which will be externally funded. We continue to encourage you, however, to develop new ideas for exploring and validating this technology. In addition to quantitation of these rare circulating cells, we are also now ready to undertake isolation of macromolecules for analysis. The isolated preparations will be provided back to you for assessment of expression in your laboratory or that of a collaborator.

These proposals should involve pilot studies for which technical feasibility and preliminary data needs to be established in order to lead to external funding and would normally be for evaluation of 10-20 samples. We will require the following information (limited to 1 page) for consideration for pilot studies:

  1. PI
  2. Study Title and Objective/Rationale (Tumor, CEC or CTC, cell quantitation or RNA)
  3. Eligible patients; desired number of samples
  4. Plans for obtaining external support (NIH, pharma, foundation based) for definitive study
  5. Contact information for research RN for scheduling and consenting purposes

If you have any questions please do not hesitate to discuss with John Pellecchia or myself. Please submit your 1 page proposals to John Pellecchia at pellecj@ccf.org. Final approval to proceed with your pilot study will be granted by Dr. Derek Raghavan and myself and should normally be available within a week of submission.

MARK YOUR CALENDARS– NCI 3rd Annual Biospecimen Research Network Symposium

Registration is now open and abstracts are being accepted for NCI's 3rd Annual Biospecimen Research Network Symposium, Advancing Cancer Research Through Biospecimen Science, March 24-25 in Bethesda, Maryland. The symposium will address the significant impact of pre-analytical biospecimen variables on cancer research and molecular medicine. Hosted by NCI's Office of Biorepositories and Biospecimen Research, the meeting will bring together leaders in the fields of biospecimen research, genomics, proteomics, oncology, pathology, biobanking, hospital administration and pharmaceutics as well as patient advocates.

For details, please click here.

FUNDING OPPORTUNITY– ACS Cancer Research Fellowship

A Call for Applications was recently released for the ACS Cancer Research Fellowship, which is intended to strengthen the field of cancer research by attracting outstanding clinicians and scientists into careers in oncology upon completion of their specialty training and to engage them in basic or clinical academic cancer research. The fellowship is not intended for those already on a research track.

Deadline: March 3

For more information, please click here.

CALL FOR APPLICATIONS– 2010 NASA Space Radiation Summer School

Applications are now being accepted for the 2010 NASA Space Radiation Summer School. Up to 15 students will be selected for the course to be held this summer at the Brookhaven National Laboratory (BNL) in Long Island, NY from May 20 – June 11. The goal of the course is to provide scientific and practical information to students and scientists who are either new to the NASA program or to charged particle radiobiology. At the completion of the summer school, students will have received the full complement of training required to conduct their own experiments at BNL.

Both foreign nationals and US citizens may apply to the program. All selected students must satisfy BNL and Department of Energy safety and security requirements in order to be admitted. Due to the intense nature of the course, applicants must demonstrate oral and written proficiency in the English language.

Deadline: February 28

For more information, please click here.

FUNDING OPPORTUNITY— Title Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)

NIH is accepting applications for the "Title Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas" (RC4) (RFA-OD-10-005).

This program will support projects that address research endeavors in specific areas that will benefit from significant three-year funds without the expectation of continued NIH funding beyond this period. The research supported by the program should have high short-term impact, and a high likelihood of enabling growth and investment in biomedical research and development, public health, and health care delivery.

This FOA solicits applications proposing to develop and implement critical research innovations in one or more of the following five thematic areas:

  1. Applying Genomics and Other High Throughput Technologies
  2. Translating Basic Science Discoveries into New and Better Treatments
  3. Using Science to Enable Health Care Reform
  4. Focusing on Global Health
  5. Reinvigorating the Biomedical Research Community

Only applications for projects that require $500,000 or more in total costs per year are expected to be considered for funding.

LOI Deadline: February 15 (requested, not required)
Proposal Deadline: March 15

For details, please click here.

Case CCC Leadership would like to review potential responses, and can assist in developing themes as responsive to the RFA.


The Small Molecule Screening Core (SMSC) has negotiated an opportunity to order shRNA clones from Sigma (in the form of glycerol stocks) for LRI and CWRU researchers for a very low price on a per clone basis. To order, please contact Anna Kondratova (kondraa@ccf.org, 445-3503). The next order will be in March, but existing clones can be purchased at any time.

Also, the SMSC has small aliquots of secondary antibodies available for purchase; each set is conjugated with DyLight 488 and DyLight 594 fluorescent dyes (Jackson ImmunoResearch Laboratories). The antibodies work well in place of fluorescein/Alexa488 & Texas Red conjugates.

Please click here for more information.

FACULTY CANDIDATE SEARCH– Associate Director for Basic Research

The Case CCC is currently accepting applications for the position of Associate Director for Basic Research. As we continue our search, we ask that people in the Cancer Center community encourage any qualified candidate to apply for the position. If you would like to nominate someone for the position, please contact Tracy Rehl (tracy.rehl@case.edu).

Click here to view the job description.


We are always trying to foster communication and collaboration across the cancer center community any way that we can. The Case CCC has set up a page on Facebook and LinkedIn, so please become a fan of us on Facebook or join our group on LinkedIn, and encourage others to do so as well. Please help us spread the word.

We encourage you to post events, relevant news articles, items of discussion, etc… Your feedback is appreciated!

CALL FOR APPLICATIONS– K12 Clinical Oncology Research Training Program

The Case CCC invites applications for its two-year NCI-funded K12 Clinical Oncology Research Training Program, led by Stanton Gerson, MD, Director, and Alvin Schmaier, MD, Co-Director.

This career development program provides interdisciplinary training in clinical and translational oncology research for clinical oncologist who are interested in pursuing academic research careers as oncology physician scientists.

Application Deadline: February 28
Start Date: July 1

For more information and application materials, please click here.


Leukemia Research Foundation Hollis Brownstein Research Grants Program
Deadline: February 15

Ohio Cancer Research Associates
Deadline: February 19

AICR Investigator Initiated Grants
Deadline: February 19

AICR Matching Grants
Deadline: February 19

AICR Postdoctoral Awards
Deadline: February 19

Hope Street Kids
Deadline: March 1

DOD Prostate Cancer Research Program (PCRP) Idea Development Awards
Pre-Application Deadline: March 3

DOD Prostate Cancer Research Program (PCRP) Synergistic Idea Development Awards
Pre-Application Deadline: March 3

CanLiv's 2010 Translational Research Grants Program
Deadline: March 5

DOD Ovarian Cancer Research Program (OCRP) Idea Award
Pre-Application Deadline: March 11

IOTF Oncology Product Research/Review Fellows
Deadline: May 30

IOTF Cancer Prevention Fellows
Deadline: September 1

AACR Scholar-in-Training Awards - Special Conferences
Deadline varies

NCI Short-Term Scientist Exchange Program
Deadline: Open

James S. McDonnell Foundation
Deadline: Open

NIH Bulletin – Notices and Funding Opportunities

IACUC 101 Workshop and PRIM&R 2010 IACUC Conference: March 21-23, 2010 in Baltimore, MD (NOT-OD-10-059)

Delays in Grant Application Submission due to Blizzard (NOT-OD-10-060)

Modification of RFA-CA-10-007 to Increase Applicants Flexibility for Proposing the Number of Clinical Trials to be Accomplished in the Funding Period (NOT-CA-10-016)

Change in Application Receipt Date for PAR-10-003 Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012 (P50) (NOT-CA-10-017)

Scientific Meetings for Creating Interdisciplinary Research Teams (R13) (PA-10-106)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax


If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to gillian.irwin@case.edu.

If you have trouble viewing this page, click here to view the newsletter online on our website.